secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2023-08-24T23:59:59+00:00
Accession:  0001193125-23-220087
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Therapeutics regains exclusive worldwide rights to ADC CX-2029 from AbbVie
--------------------------------------------------------------------------------

- Regained full worldwide rights to develop CX-2029, a CD71-targeting conditionally activated antibody drug conjugate.
- AbbVie eligible for tiered sales royalties on CX-2029 ranging from low-to-mid single digit percentages.
- CytomX to pay Seagen potential future milestones and tiered sales royalties (mid-to-high single digits) for linker payload tech.
- Transition Agreement supersedes the terminated 2016 CD71 Co-Development and License Agreement with AbbVie.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312523220087/0001193125-23-220087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312523220087/d489987d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-220087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer